Immunology and inflammation

News

Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.

News

Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.

News

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.

News

Faced with the prospect of running out of cash, Jasper Therapeutics has merged with Kira Pharma, fortified by $132m in new private funding.

News

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.